Clinical trials: Respiratory Symptoms
COPD
Nasal High Flow (NHF) in COPD - Effects on Ventilation in Wakefulness
Controlled randomized crossover trial in patients with chronic obstructive respiratory disease (COPD), who are treated with Nasal High Flow (NHF) therapy during wakefulness with a small amount of CO2 added to the inhaled air to…
- Trial name
- NCT05053074
- Testing
- Nasal High Flow (NHF)
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- Institut für Pneumologie Hagen Ambrock eV
Post-Acute COVID-19 Syndrome
A Study of Apabetalone in Subjects With Long -COVID
This is an open label, multicentre, phase II clinical trial that aims to assess the efficacy and safety of oral Apabetalone with background dapagliflozin for up to 12 weeks in T2DM patients with a history of probable or confirmed…
- Trial name
- NCT06590324
- Testing
- Apabetalone
- Where
- 3 sites in Jordan, Saudi Arabia and 1 more
- Volunteers
- 200 people
- Sponsor
- Resverlogix Corp
Pulmonary Disease, Chronic Obstructive
Clinical Study to Assess the Effects of SRT2104 and Prednisolone on Biomarkers in Blood in Healthy Volunteers
The primary purpose of this study is to assess the pharmacodynamic effect of single, oral doses of SRT2104 (250 mg, 500 mg, 1000 mg, 2000 mg) and prednisolone as measured by levels of ex vivo LPS-induced TNF-alpha production in…
- Trial name
- NCT00920660
- Testing
- 0.25g SRT2104, Prednisolone, 0.5g SRT2104
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cough
Clinical Trial of the Safety and Tolerability of MMH-522 in Healthy Volunteers
Open-label, non-comparative, non-randomized clinical trial of the safety and tolerability of the drug MMH-450 in healthy volunteers consisting of 4 consecutive stages
- Trial name
- NCT07754279
- Testing
- MMH-522
- Where
- Russia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Materia Medica Holding
Chronic Obstructive Pulmonary Disease (COPD) With Cachexia
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
This study will assess the pharmacodynamics, pharmacokinetics, safety and tolerability of BYM338 in patients with COPD and cachexia. The primary outcome will be a change in thigh muscle volume compared to placebo.
- Trial name
- NCT01669174
- Testing
- BYM338
- Where
- 9 sites in United States, Netherlands and 1 more
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Symbicort in Chronic Obstructive Pulmonary Disease
Under daily routine conditions and without any intervention by the sponsor regarding the selection of subjects, diagnostic procedures, therapeutic decisions (medicinal and non- medicinal therapy, dose, duration, etc.), routine…
- Trial name
- SYMBOL (NCT00611520)
- Volunteers
- 64,730 people
- Sponsor
- AstraZeneca
Rhinitis
Safety Study of Levocetirizine Oral Solution for Japanese Pediatrics
To evaluate the safety of treatment with levocetirizine oral solution in pediatric patients aged form 6 months to 2 years old with allergic rhinitis or pruritus associated with the skin diseases.
- Trial name
- NCT01563081
- Testing
- Levocetirizine
- Where
- 7 sites in Japan
- Volunteers
- 60 people
- Sponsor
- GlaxoSmithKline
Sleep Apnea Syndromes, Insomnia
Evaluation of the Reliability and Validity of a Diagnostic Sleep Disorders Questionnaire
The study aims to develop and test a user-friendly, accessible approach to sleep assessment which can function as an initial "triage" of targeted sleep conditions, such as insomnia, insufficient sleep syndrome, sleep apnea…
- Conditions
- Sleep Apnea Syndromes, Insomnia, Insufficient Sleep Syndrome, Circadian Rhythm Disorders
- Trial name
- NCT03468400
- Where
- 2 sites in United States, Israel
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Dayzz Live Well Ltd.
COPD, Cachexia
Pilot Study of Safety and Tolerability of Nutrifriend Cachexia in COPD Cachexia
SF-K002 is a pilot study in patients with moderate to severe COPD suffering from involuntary weight loss. The study is 12 weeks, double-blinded, placebo controlled and the main objective is to study the safety and tolerability of…
- Trial name
- NCT02442908
- Testing
- Nutrifriend Cachexia
- Where
- 4 sites in Sweden
- Volunteers
- 45 people
- Sponsor
- Smartfish AS
Ear Deformities, Acquired, Ear; Deformity, Congenital
Evaluation of the Auryzon Devices in the Optimization of Ear and Nose Reconstruction Procedures
This study evaluates the efficacy of the AuryzoN devices in the ear and nose reconstruction surgeries, both in terms of operative time and overall quality of reconstruction.
- Conditions
- Ear Deformities, Acquired, Ear; Deformity, Congenital, Microtia, Nose Deformity
- Trial name
- NCT03624608
- Testing
- AuryzoN Family of Devices
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Reconstrata, LLC
Chronic Obstructive Pulmonary Disease, Chronic Bronchitis
To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD
The purpose of this study is to determine the long-term safety of arformoterol over a period of 12 months in subjects with COPD
- Conditions
- Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema
- Trial name
- NCT00064415
- Testing
- arformoterol, Salmeterol
- Where
- 90 sites in United States
- Volunteers
- 799 people
- Sponsor
- Sumitomo Pharma America, Inc.
Chronic Obstructive Pulmonary Disease (COPD)
Utility of Remote Lung Auscultation in Transitions of Care After Pulmonary Exacerbations of COPD
Listening to breath sounds with the stethoscope/auscultation is used by pulmonary physicians in conjunction with pulmonary function, signs and symptoms, oxygen saturation and diagnostic testing to admit, follow and discharge…
- Trial name
- NCT05661435
- Testing
- RESP Biosensor
- Where
- 2 sites in United States
- Sponsor
- Strados Labs, Inc.
Hypoxia
In Vivo Pulse Oximeter Validation Study
The goal of this clinical trial is to compare values of SpO2 provided by the DUT and the SaO2 used as a reference in healthy adults.
- Trial name
- NCT05873335
- Testing
- Mixtures of nitrogen, air, and carbon dioxide
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Gabi SmartCare
Non-small Cell Lung Cancer With EGFR-Activating Mutations
ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.
This is a multinational, multicenter, randomized, open-label, Phase 3 study comparing the efficacy and safety of treatment with dacomitinib (PF-00299804) to treatment with gefitinib in patients with locally advanced or metastatic…
- Trial name
- NCT01774721
- Testing
- Dacomitinib (PF-00299804), Gefitinib
- Where
- 52 sites in China, Hong Kong and 5 more
- Volunteers
- 452 people
- Sponsor
- Pfizer
Diarrhea, Acute Respiratory Infection
Oral Supplement for Pregnant and Lactating Mothers
To assess protection against early life infections through supplementation of mothers during pregnancy to the newborns' growth, morbidity, immune status intra and extra-uterine.
- Trial name
- NCT01073033
- Testing
- milk supplement 1, milk supplement 2
- Where
- Philippines
- Volunteers
- 234 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Respiratory Insufficiency, Dyspnea
HVNI Ambulation Feasibility Study
The pilot/feasibility study evaluates the ability of High Velocity Nasal Insufflation (HVNI) therapy to facilitate ambulation and mobilization in patients experiencing shortness of breath, as compared to simple oxygen therapy.
- Trial name
- NCT03885726
- Testing
- Precision Flow Plus, Treatment as Usual
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Vapotherm, Inc.
Chronic Obstructive Pulmonary Disease
Safety Study to Evaluate MN-221 in Chronic Obstructive Pulmonary Disease (COPD) Patients
In MediciNova's clinical development plan for MN-221, it was recognized that treatment of COPD exacerbations may necessitate more than one single i.v.
- Trial name
- NCT01551316
- Testing
- MN-221
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- MediciNova
Chronic Obstructive Pulmonary Disease (COPD)
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Cavosonstat Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: The purpose of this study is to to evaluate the efficacy and safety of Cavosonstat administered twice daily compared with Placebo for 24 Weeks in adult subjects with Chronic Obstructive Pulmonary Disease (COPD)…
- Trial name
- NCT04600778
- Testing
- Cavosonstat 5 mg, Cavosonstat 10 mg, Cavosonstat 25 mg
- Volunteers
- 108 people
- Sponsor
- GSNOR Therapeutics, Inc.
Atrial Fibrillation, Venous Thromboembolism
Verification of XAPPORT: a Decision Support App for Physicians Used for Patients Anticoagulated With Rivaroxaban in Terms of Anticoagulation Management in Elective Surgery: Verification Process of Medical Decision Algorithm
This study shall determine whether XAPPORT - a mobile device app based on different guidelines, the summary of product characteristics of rivaroxaban, and clinical facts and practice - provides adequate guidance to physicians…
- Conditions
- Atrial Fibrillation, Venous Thromboembolism, Pulmonary Embolism
- Trial name
- VeriXAPPORT (NCT02900404)
- Testing
- XAPPORT, Expert Panel ("gold standard")
- Sponsor
- Bayer
COPD, Chronic Obstructive Pulmonary Disease
A Study to Assess the Effects of PT001 and PT005 MDI on Specific Image Based Parameters in Subjects With Moderate to Severe COPD
To assess the effect of treatment with Glycopyronnium (GP) MDI administered twice daily (BID) and Formoterol Fumarate (FF) MDI administered BID on specific image-based airway volumes and resistance in subjects with moderate to…
- Trial name
- NCT02937584
- Testing
- GP MDI (PT001) 14.4 μg, FF MDI (PT005) 9.6 μg
- Where
- 2 sites in Belgium
- Volunteers
- 23 people
- Sponsor
- Pearl Therapeutics, Inc.